NOV 03, 2016 10:30 AM PDT

Found in Translation: ST2 From Discovery to Clinical Adoption

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • President, Critical Diagnostics
    Biography
      Dr. James V. Snider, Ph.D., has been the President of Critical Care Diagnostics Inc. since August 2005 and serves as its Member of the Management Board. Prior to joining CCD in August 2005, Dr. Snider Served as a Executive Vice President of Business and Operations of Intelligent Medical Devices Inc. Dr. Snider joined Intelligent MD in October 2001 as Vice President of Marketing and Business Development. Prior to IMD, Dr. Snider served a series of marketing and product development positions at Applied Biosystems (ABI). In his last role at ABI, he managed the Sample Preparation Systems product line and team from genesis through product launch and successfully established it in the market. Before his eight-year tenure at AB, Dr. Snider served as Senior Scientist at Biotech Research Laboratories, a contracts and service research company specializing in retroviral technologies. He performed his post-doctoral research as a fellow in the Biological Response Modifiers Program at the Frederick Cancer Research & Development Center of the National Cancer Institute. Dr. Snider holds a BS in chemistry from Grand Valley State University, a PhD in chemistry from the University of South Carolina and an MBA in technology management from the University of Phoenix.

    Abstract:

    Laboratory tests come into existence through a variety of processes but regardless of the genesis all share a certain set of requirements. These include discovery, development, validation, regulatory clearance and market adoption. ST2 is a protein biomarker that was discovered in a gene expression exploration analysis to be involved in cardiac disease and to potentially have clinical value in managing patients with cardiac disease. Following this discovery Critical Diagnostics developed an in vitro diagnostic assay to accurately measure ST2 and performed the necessary clinical studies to determine the clinical value proposition. This information was used to pursue and obtain regulatory approval and the test is now available in most of the world. This lecture will cover the processes and issues from taking a biomarker target from discovery through to commercialization.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    Loading Comments...